Asia-Pacific: The Fastest-Growing Regional Market

The Asia-Pacific region is projected to be the fastest-growing market for CIDP treatments, fueled by rapidly improving healthcare infrastructure and increasing awareness in China, Japan, and India. As these nations invest in neurology specialist training and diagnostic facilities, the rate of CIDP identification is surging, creating a massive new demand for maintenance therapies. Detailed statistics for the APAC region are featured in the CIDP Market study.

People also ask: Is the CIDP market growing in Asia? Why are autoimmune diseases increasing in the APAC region? The combination of a large population base and the rising adoption of Western-style healthcare models is driving global pharmaceutical companies to expand their footprint in this region.

Local manufacturing of biosimilars and plasma-derived products is also expected to lower treatment costs in Asia, making life-saving therapies more accessible to a broader demographic. This localized production is a key strategy for capturing market share in price-sensitive emerging economies.

Mehr lesen